

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

Patterns and functional consequences of antibody speciation in maternal-fetal transfer of coronavirus-specific humoral immunity

Andrew P. Hederman¹, Hannah M. Brookes¹, Harini Natarajan², Leo Heyndrickx³, Kevin K. Ariën^{3,4}, Joshua A. Weiner¹, Amihai Rottenstreich⁵, Gila Zerbiv⁶, Dana Wolf⁶, Tessa Goetghebuer^{7,8}, Arnaud Marchant⁷, Margaret E. Ackerman^{1,2#}

¹Thayer School of Engineering, Dartmouth College, Hanover, NH, USA

²Department of Immunology and Microbiology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA

³Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.

⁴Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.

⁵Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center

⁶Clinical Virology Unit, Hadassah University Medical Center, Jerusalem, Israel

⁷Institute for Medical Immunology, Université libre de Bruxelles, Charleroi, Belgium

⁸Pediatric Department, CHU St Pierre, Brussels, Belgium

#Corresponding Author

Margaret E. Ackerman

14 Engineering Drive

Hanover, NH 03755

margaret.e.ackerman@dartmouth.edu

(ph) 603 646 9922

(fax) 603 646 3856

30 **Abstract**

31 Maternal antibodies serve as a temporary form of inherited immunity, providing humoral
32 protection to vulnerable neonates. Whereas IgG is actively transferred up a concentration gradient via the
33 neonatal Fc Receptor (FcRn), maternal IgA and IgM are typically excluded from fetal circulation. Further,
34 not all IgG molecules exhibit the same transfer efficiency, being influenced by subclass, Fab and Fc
35 domain glycosylation, antigen-specificity, and the temporal dynamics of maternal antibody responses.
36 Here, we investigate the phenotypes and functions of maternal and cord blood antibodies induced by
37 SARS-CoV-2 infection and compare them to those induced by mRNA vaccination, focusing on breadth of
38 antigen recognition and antiviral functions including neutralization and effector function. While cord blood
39 coronavirus-specific antibody functional breadth and potency appeared to be more compromised than
40 binding breadth and potency in both groups, vaccination induced substantially greater function and
41 breadth in cord blood than did natural infection. These functional phenotypes were associated with
42 speciation of the maternal serum repertoires, as some IgG subpopulations were enriched while others
43 were relatively depleted. Relevant to the continued protection of vulnerable populations in the context of a
44 diversifying pathogen, greater breadth was observed for antibody effector functions than for
45 neutralization, and these activities were associated with greater affinity for antigen. This work provides
46 insights into the functional breadth of maternal-fetal antibody responses in the context of novel mRNA
47 vaccines and a recently emerged pathogen that is likely to be a public health burden for the foreseeable
48 future.

49 **Introduction:**

50 The current COVID-19 pandemic continues to infect and cause severe disease in many
51 individuals. While the global death rate has declined, it is estimated that even in a relatively well-
52 vaccinated population like the United States, 3,000 deaths per month are attributable to Severe Acute
53 Respiratory Syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for COVID-19¹. The virus'
54 sequence has diverged over time into numerous variants with differing degrees of susceptibility to
55 antibodies induced by exposure to prior variants. Notable variants, including Alpha (B.1.1.7), Beta
56 (B.1.351), Gamma (P.1), Delta (1.617.2), and Omicron (B.1.1.529) have shown the ability, albeit at
57 varying levels, to evade neutralizing antibody responses²⁻¹¹. Across each of these waves of prevalent viral
58 variants, certain populations of individuals remain at greater risk than others for severe COVID-19
59 following infection. Fortunately, while initial vaccine clinical trials did not include pregnant participants,
60 recent data has shown that following vaccination, pregnant women achieve robust antibody responses
61 that are comparable to non-pregnant individuals, while maintaining similar safety profiles, and that
62 vaccination is highly effective in preventing severe disease and death in birthing women¹²⁻²².

63 Further, because mammals have evolved to transmit maternal humoral immunity to the
64 fetus/neonate in the form of antibodies transferred across the placenta and via breastmilk, maternal
65 vaccination has the multifaceted goal of not only protecting the mother but also of generating a sufficiently
66 robust antibody response to protect the fetus in utero as well as the neonate during early life²³. Indeed,
67 whether induced by infection or vaccination, the “inheritance” of maternal antibody is a crucial component
68 of neonatal immunity early in life against infectious diseases^{24,25}. While not especially susceptible to
69 COVID-19 morbidity and mortality, neonates and children remain at risk of long term post-acute sequelae
70 of COVID-19 (PASC)²⁶. Although rare, these complications can be severe including multisystem
71 inflammatory syndrome in children (MIS-C)²⁷. Additionally, while both maternal infection and maternal
72 vaccination are known to influence maternal and neonatal infection risk, at least for some variants²⁸⁻³⁰,
73 they induce maternal antibody responses with a number of differing attributes, providing an opportunity to
74 evaluate transfer biases and their impacts.

75 Transport of IgG across the placenta is mediated by binding to the neonatal Fc receptor (FcRn)
76 expressed on syncytiotrophoblast cells³¹⁻³⁴. Intriguingly, these antibodies do not bind to FcRn on the cell
77 surface, but rather are rescued from degradation following fluid phase uptake, internalization, and
78 acidification of endosomal compartments by a pH-dependent protonation of the Fc domain, which results
79 in increased affinity to FcRn³⁵. As FcRn is then sorted and cycled back to the cell surface, it salvages
80 bound IgG, releasing it at the neutral pH of the extracellular environment. The efficiency of this rescue
81 and transfer across the otherwise highly selective barrier between generations is associated with many
82 factors, including maternal IgG levels over time, IgG subclass and allotype, post-translational
83 modifications on both antigen-binding and Fc domains, and antigen-specificity³⁶⁻⁴³. While some of these
84 factors are thought to drive these differences by directly altering FcRn binding affinity or kinetics, the
85 mechanism(s) whereby other factors relate to transfer phenotypes remains incompletely understood⁴⁴⁻⁴⁶.

86 Studies have started to look at the transfer of antibodies following maternal mRNA vaccination against
87 SARS-CoV-2^{38,47-49}; however, a more thorough analysis of the phenotypes and activity of the transferred
88 antibodies could provide insight into both protection of neonates from COVID-19 as well as to other
89 infectious diseases by informing on attributes and activities of maternal immune responses that might
90 provide for the best defense of vulnerable neonates.

91 Previous analysis of vaccinated pregnant women has revealed generation of neutralizing SARS-
92 CoV-2 specific antibodies as well as antibodies capable of eliciting Fc-mediated effector functions in
93 mothers⁵⁰⁻⁵². These same antibody attributes are typically present in cord blood at delivery⁵¹. In other
94 contexts, however, they are not always present at the levels expected based on antibody titers, indicating
95 that while generally well-correlated with maternal serum antibodies at the time of delivery, relative activity
96 of antibodies in cord blood are distinct. Studies reporting differences in quantity and quality of transferred
97 antibodies have cited numerous factors including maternal antibody levels, FcRn expression level, IgG
98 glycosylation, IgG subclass, and antigen-specificity, among others, as potential explanations³⁶⁻⁴³. While it
99 is well understood that vaccination- and natural infection-induced antibody responses differ in terms of
100 mucosal compartmentalization, induced isotype balances, and epitope-specificities, what remains less
101 well studied is the breadth of the antibody functional response in mothers as it compares to matched cord
102 blood to SARS-CoV-2 variants of concern (VOC) following these exposures⁵³⁻⁵⁸. These factors are
103 important as the virus continues to diversify, population-level uptake of updated and booster vaccinations
104 decline⁵⁹, and efforts continue toward a universal vaccine⁶⁰. Overall, understanding the breadth of the
105 antibody functional response in vaccinated and convalescent mothers with corresponding matched cord
106 blood samples can provide new insights into how neonates may benefit from maternal antibodies, in the
107 context of compromised or lost neutralization activity associated with viral variation over time and the
108 absence of pathogen-specific IgA and IgM. These insights into the maternal and inherited antibody
109 repertoires have implications for how vaccines can be most effectively developed as new variants
110 continue to emerge for SARS-CoV-2 as well as for other infectious agents posing risks to neonates and
111 infants.

112

113

114 **Results**

115 ***Distinct antibody responses among cord blood samples from vaccinated and convalescent*** 116 ***mothers to SARS-CoV-2 variants***

117 To explore antibody profiles to SARS-CoV-2 variants, maternal and matched cord blood serum
118 samples were collected from vaccinated (n=50, Hadassah Medical Center, Israel) and convalescent
119 maternal study participants (n=38, CHU St. Pierre, Belgium) after immunization against or infection by
120 SARS-CoV-2 in the third trimester early in the pandemic (**Supplemental Table 1**). These samples were
121 profiled for antibody magnitude, specificity, and Fc domain characteristics of SARS-CoV-specific IgM, IgA,
122 and IgG across a panel of variants and pertussis and tetanus toxoids as control or comparator

123 specificities that are also relevant to neonatal health (**Supplemental Table 2**). We first explored the
124 antibody binding responses to SARS-CoV-2 Wuhan and VOC in maternal and cord blood as a
125 representation of antibody profiles in neonates born to vaccinated and convalescent mothers. Antibody
126 profiles differed in association with both maternal exposure history and sample type, as shown from the
127 distinct clustering by Uniform Manifold Approximation (UMAP) (**Figure 1A**). Responses among maternal
128 blood samples clustered closely together, while those in cord samples formed a distinct cluster. Within
129 each of these sample type groups, vaccinated and convalescent subjects formed distinct sub-clusters.

130 Among individual features of the antibody response that were assessed, higher levels of variant-
131 specific IgM but lower levels of variant-specific IgG antibodies were observed in maternal blood from
132 convalescent as compared to vaccinated subjects (**Figure 1B**). Intriguingly, despite the expectation that
133 IgA and IgM would be absent from cord blood samples, some of these responses were nonetheless also
134 elevated in cord blood samples from neonates whose mothers were convalescent (**Figure 1B**). Given
135 these surprising results, responses measured in each sample were compared with blood samples from
136 naïve subjects across each isotype for SARS-CoV-2 variants and control antigens (**Figure 1C**). In
137 general, IgM and IgA reactivity toward all of the antigens tested were considerably lower in cord blood
138 than even serum samples from SARS-CoV-2 naïve subjects, consistent with the presence of natural or
139 cross-reactive IgM and IgA antibodies with some ability to bind all of the antigens tested, and the
140 expected lack of IgA and IgM in cord blood. However, levels were not the same in cord blood samples
141 from vaccinated as compared to convalescent dyads for a specific subset of SARS-CoV-2 antigens,
142 including beta, delta, and omicron variants. Elevated IgM and IgA responses to these three antigens in
143 cord blood of convalescent mothers were sufficient to lead to greater activity in both breadth-potency
144 curves (**Figure 1D**), as well as breadth scores (**Figure 1E**). Similar elevations were also observed for IgM
145 binding to the receptor binding domain (RBD) for gamma, delta, and omicron and for IgA binding to
146 omicron (**Supplemental Figure 1**). Neither of the control antigens tested showed this pattern, suggesting
147 that this signal is not the result of transfer of small quantities of these isotypes stemming from maternal
148 infection. An explanation for this phenotype was not readily apparent, though some combination of
149 specific mutations, distinct mutations in specific positions, conformationally-distinct epitopes, post-
150 translational modifications, or other factors may contribute to these unique binding profiles.

151 In contrast to IgM and IgA responses, the breadth of IgG responses was elevated in association
152 with vaccination as compared to infection for maternal blood, as previously reported for this cohort. This
153 elevation was also apparent in cord blood (**Figure 1D-E**). For both exposure histories, IgG binding
154 breadth was comparable between maternal and cord blood (**Figure 1C-E**). The breadth of RBD-specific
155 IgG also exhibited the same consistency between maternal and cord blood within each group
156 (**Supplemental Figure 1**), further demonstrating the efficiency of placental transfer even when
157 seroconversion does not occur until during the third trimester. In sum, greater coverage of diverse
158 variants is expected in infants whose mothers were immunized rather than infected based on their
159 elevated IgG responses.

160

161 ***IgG subclass and FcγR breadth of antibodies in cord blood to SARS-CoV-2 variants differs***
162 ***between vaccination and natural infection***

163 Given the stark differences in IgG binding breadth associated with exposure history, we explored
164 the breadth of IgG subclasses and Fcγ Receptor (FcγR) binding of spike- (S), RBD-, and control antigen-
165 specific antibodies in cord blood samples (**Figure 2, Supplemental Figures 2-3**). IgG1 and IgG3
166 responses exhibited the greatest breadth, followed by IgG2; IgG4 responses were uncommon (**Figure**
167 **2A, left; Supplemental Figure 2**). Comparing between exposure histories, while breadth scores for all
168 subclasses were higher following maternal vaccination than infection, this difference was only statistically
169 significant for IgG3 (**Figure 2B, top**). FcγR binding antibody breadth-potency curves were similar among
170 the receptors tested (**Figure 2A, right**), and like IgG3, breadth scores were significantly increased in cord
171 blood following maternal vaccination as compared to infection (**Figure 2B, bottom**). Given the varying
172 roles of these subclasses and FcγR to antibody effector functions, these differences may be relevant for
173 the *in vivo* antiviral activity of cord blood antibodies.

174

175 ***Biases in the specificity and subclasses of well-transferred IgG***

176 We next explored IgG transfer ratios (cord/maternal responses) to evaluate the extent to which
177 antibody sub-populations were differentially transferred to cord blood when mothers were exposed to
178 spike by natural infection or vaccination. Whereas total IgG specific for tetanus and pertussis control
179 antigens was enriched in cord blood (**Figure 2C-D**), there was less total IgG specific for SARS-CoV-2 S
180 protein present in cord blood than maternal blood for both Wuhan and the most distant VOC, Omicron
181 (**Figure 2C**). Indeed, for dyads exposed to SARS by either vaccination or natural infection, median levels
182 of total IgG binding to S were decreased in cord as compared to maternal blood (**Figure 2D**). Among the
183 IgG subclasses, IgG1 was better transferred than IgG2, which was in turn better transferred than IgG3.
184 This pattern or relative differences was consistent across specificities and groups (**Figure 2C-D,**
185 **Supplemental Figure 4**). However, the absolute magnitudes differed: transfer efficiency of pertussis and
186 tetanus-specific IgG1, IgG2, and IgG3 was greater than that of SARS-CoV-2-specific subclasses, and
187 transfer efficiency in vaccinated dyads tended to be greater than that observed in convalescent dyads.

188

189 ***mRNA vaccination shows increased antibody Fc effector functions and transfer of functional***
190 ***antibodies compared to natural infection***

191 Given these biases in SARS-CoV-2 specific IgG phenotypes between maternal and cord blood
192 samples, we next defined the ability of antibodies in cord blood from vaccinated and convalescent dyads
193 to elicit Fc-mediated effector functions in *in vitro* assays. For each sample, we measured phagocytosis
194 (ADCP), antibody dependent cellular cytotoxicity (ADCC), and complement deposition (ADCD) at three

195 serum concentrations (**Figure 3A**, compared to maternal levels and for RBD in **Supplemental Figures 5-**
196 **6**). For cord blood samples from vaccinated dyads, functional activity was well conserved across variants,
197 whereas for the convalescent dyad cord blood samples, there was low activity against the Wuhan strain,
198 and considerable reduction apparent in functional activity to most VOC across all effector functions. In
199 contrast to SARS-CoV-2-specific responses, both vaccinated and convalescent cord blood samples
200 showed robust functional activity to both tetanus and pertussis control antigens across all three functional
201 assays (**Figure 3A**). Unlike SARS CoV-2-specificities, levels of activity were similar for the control
202 antigens in cord blood drawn after maternal infection as after maternal vaccination.

203 In vaccinated dyads, functional breadth scores were similar between maternal and cord blood
204 samples for both spike (**Figure 3A**) and RBD antigens (**Supplemental Figure 6**), suggesting that Fc
205 mediated effector functions induced by vaccination and transferred *in utero* can be quite broad. However,
206 like the IgG binding responses, functional breadth was greater in cord blood from vaccinated than
207 convalescent dyads (**Figure 3A, inset**). For ADCP, ADCC, and ADCD, vaccinated maternal-cord pairs
208 showed transfer ratios that tended to be around one, with slightly higher values for closer VOC, and lower
209 values for more distant VOC (**Figure 3B-C, Supplemental Figure 7**). Convalescent dyads showed a
210 significantly different profile, with transfer ratios of around one for the Wuhan spike, but a significant
211 reduction in transfer ratio of functional antibodies against VOC. Thus, the decreased magnitude of
212 antibody responses in convalescent mothers is further compounded by decreased transfer efficiency,
213 leaving neonates with considerably lower antibody effector activity against VOC. Again, in contrast to
214 observations for SARS-CoV-2 antigens, control antigens typically exhibited functional transfer ratios
215 greater than or equal to one in both groups (**Figure 3B-C**).

216

217 ***Effector functions may contribute to protection of neonates in the absence of neutralization***

218 Although loss of neutralization has been reported elsewhere for the Omicron variant⁶¹, this loss
219 was confirmed for the participants in this study. Neutralization tests against the Wuhan and Omicron
220 variants were performed for a subset of subjects (**Figure 3D**). Further, cord blood samples exhibited
221 lower neutralization activity than did maternal blood against the Wuhan strain, consistent with prior
222 reports⁶². Neutralization activity was greater for vaccinated as compared to convalescent dyads, and
223 limited neutralization was observed against the Omicron variant. The transfer efficiency of neutralizing
224 antibodies was poorer than that of antibodies with effector function; it was also lower in convalescent than
225 vaccinated dyads (**Figure 3E**). Collectively, these results suggest that effector function has the potential
226 to contribute to protection of neonates in cases where neutralization activity is lost or insufficient.

227

228 ***Antibody functions are differentially mediated by immunoglobulin isotype***

229 With prior data showing differences in immunoglobulin (Ig) isotype binding in cord as compared to
230 maternal blood and functional and transfer efficiency differences associated with maternal exposure

231 history, we next explored the role each isotype played in eliciting effector functions (**Figure 4**). Serum
232 from maternal and cord blood was depleted of IgM, IgA, or IgG and tested for each effector function
233 following confirmation of the efficiency (**Figure 4A**) and specificity (**Supplemental Figures 8-9**) of
234 depletion. Functional responses for maternal and cord blood samples from vaccinated dyads were
235 completely dependent on IgG, as depleted samples showed a near complete loss of functional activity
236 (**Figure 4B-D**). In contrast, despite the presence of these additional isotypes, depletion of IgM or IgA from
237 vaccinated dyads had no effect on these effector functions. Maternal and cord blood samples from
238 convalescent dyads also showed dependence on IgG for ADCP and ADCC function (**Figure 4B-C**), but
239 exhibited a unique profile for ADCD. For the maternal convalescent group, ADCD activity was significantly
240 reduced by IgG depletion, but the magnitude of this reduction was relatively smaller than for other sample
241 types, accounting for only about 10-25% of ADCD activity, the majority of which could instead be
242 attributed to IgM (**Figure 4D**). Collectively, this data showed that ADCD activity was variably induced by
243 IgM or IgG isotypes, depending on antigen exposure history.

244

245 ***Functional responses to endemic and emergent pathogenic coronaviruses***

246 Lastly, induction of immunity beyond SARS-CoV-2 VOC, to other sarbeco- and further CoV
247 families is clinically desirable. The breadth of recognition of SARS-CoV-1 and endemic CoV spike
248 proteins are known to vary in association with SARS-CoV-2 spike exposure history^{63,64}. The differences in
249 antibody functional breadth among vaccinated and convalescent dyads across CoV-2 variants led us to
250 explore to what extent this breadth encompasses more distant CoV. We tested binding and effector
251 functions of antibody responses specific for endemic beta CoV HKU1, and OC43, and alpha CoV NL63,
252 and 229E, along with emergent pathogenic SARS-CoV-1 and MERS (Middle Eastern Respiratory
253 Syndrome)-CoV. Among the endemic CoV, which have long circulated in the human population, the beta
254 CoV HKU1 and OC43 are more closely related to SARS-CoV-2 than the alpha CoV NL63 and 229E,
255 providing an opportunity to look at the response to a panel of circulating viruses that differ in their degree
256 of similarity. Likewise, we explored binding and functional responses to SARS-CoV-1 and MERS-CoV to
257 examine what breadth may exist for these viruses to which the dyads evaluated here are presumed
258 naïve.

259 Levels of IgM, IgA, and IgG specific to SARS-CoV-1 but not MERS S protein were elevated in
260 maternal samples from both convalescent and vaccinated dyads as compared to naïve subjects (**Figure**
261 **5A**). However, different dilutional profiles were observed for these CoV-1 S-specific IgG responses: while
262 infection and vaccination resulted in similar levels of binding antibody detection when serum was tested at
263 a 1:2,500 dilution, when diluted further to 1:5,000, this signal was lost for convalescent subjects while
264 being maintained for vaccinated subjects. As described previously for SARS-CoV-2 antigens, the testing
265 of cord blood samples made clear the detection of low levels of IgM and IgA that react to SARS-CoV-1
266 and MERS S in even naïve subjects (**Figure 5A**). Similarly, IgM and IgA responses to endemic CoV could

267 be detected in maternal blood by virtue of their absence from cord blood (**Figure 5B**). Whereas
268 vaccination to CoV-2 induced elevated IgG responses to CoV-1 as compared to natural infection when
269 diluted serum samples were tested, the opposite pattern was observed for OC43: infection induced a
270 greater degree of OC43-specific IgG detected at a 1:5,000 dilution, while similar levels were observed
271 when samples were tested at a higher concentration.

272 Despite the presence of binding antibodies to diverse CoV in both convalescent and vaccinated
273 dyads, antibody effector functions were more limited (**Supplemental Figure 10**). Effector functions were
274 observed in both maternal and cord blood samples of vaccinated but not convalescent dyads for CoV-1
275 spike (**Figure 5C**), consistent with the binding profiles of dilute serum. These effector functions were
276 present at similar levels in maternal and cord blood, and were lost following IgG depletion (**Supplemental**
277 **Figure 11**).

278 Among endemic CoV, vaccinated dyads exhibited only ADCP activity against only stabilized
279 OC43 S2P (**Supplemental Figure 10**), and activity was similar between maternal and cord blood
280 samples. In contrast, convalescent dyads exhibited a diversity of effector functions directed to OC43 S
281 (**Figure 5D**). Consistent with IgG binding across endemic CoV S sub-domains (**Figure 5E**), this activity
282 extended to the OC43 S2 domain (**Figure 5F**), but not to conformationally-stabilized OC43 S2P
283 (**Supplemental Figure 10**). Again, despite the presence of IgM and IgA specific for endemic CoV (**Figure**
284 **5B,E**), IgG depletion essentially eliminated all observed activity (**Supplemental Figure 11**).

285 Due to the distinctions in Fc effector functions and the surprisingly differential dilution-
286 dependence of IgG binding profiles observed for CoV-1 S and OC43 S2 among vaccinated and
287 convalescent samples, we explored if there may be differences in IgG affinity between these groups using
288 biolayer interferometry (BLI) on a subset of samples. Indeed, whereas the total level of binding IgG
289 antibodies was similar to OC43 S2 for vaccinated and convalescent dyads, affinities were distinct among
290 the groups (**Figure 5G-I**). Convalescent dyad samples (n=5) showed binding profiles consistent with
291 higher affinity (multiple orders of magnitude) than the vaccinated dyads, exhibiting the slow on- and slow
292 off-rate profile typical of high affinity interactions. Consistent with functional data, these affinities were
293 lower in convalescent cord than in maternal blood, suggesting a possible explanation for the decreased
294 ADCP, ADCC, and ADCD activity observed in cord blood samples. In contrast, IgG from vaccinated
295 dyads exhibited lower magnitudes and the fast on-, fast off-rate profile commonly seen in low affinity
296 interactions. This latter profile was consistent with that observed in naïve individuals, suggesting that
297 infection induces either recall of pre-existing and/or induction of novel cross-reactive antibodies with high
298 affinity, whereas vaccination does not. Using the same method, we explored whether these affinity
299 differences were specific to OC43 S2 by measuring affinities across a panel of antigens (**Figure 5 H-I**).
300 Across antigens and serum IgG samples, affinities tended to be marginally lower in cord blood than
301 corresponding maternal samples. Greater differences were observed between vaccinated and
302 convalescent IgG samples. The median affinity of vaccine-elicited IgG binding to Wuhan S exceeded that
303 of IgG induced by natural infection. Relative to Wuhan S, affinity to the Omicron variant was reduced in

304 both dyad groups, however, the reduction was greater for convalescent than vaccinated dyads (**Figure 5**
305 **H**). This pattern held with respect to CoV-1 S as well, against which affinity was further decreased. In
306 contrast to emergent CoV, but like the OC43 S2 domain, affinity for OC43 S was greater in convalescent
307 dyads. Vaccinated dyads demonstrated similar affinities for OC43 as were observed in the SARS-CoV-2
308 naïve subjects. Thus, these affinities corresponded well with effector function profiles: higher effector
309 function and IgG affinity for SARS-CoV-2 antigens were observed in vaccinated dyads, whereas higher
310 effector function and IgG affinity for endemic CoV OC43 antigens were observed in convalescent dyads.
311 These results link effector function to antigen binding affinity as qualitative measures of a polyclonal
312 antibody response that can be distinct from response quantity or magnitude.

313

314 **Discussion**

315 The distinct antibody responses to SARS-CoV-2 VOC, endemic, and emergent coronavirus
316 antigens in maternal and cord blood samples from vaccinated and convalescent dyads captured in this
317 study likely result from an array of contributing factors, including antigen conformations, maternal
318 antibody transfer dynamics, affinity differences, and antigen exposure history, among others. A deeper
319 understanding of these factors in the context of pregnancy has the potential to help inform future
320 development of maternal vaccines targeted to contribute to the protection of neonates, particularly as the
321 virus continues to diverge in response to immune pressure mediated by humoral and cellular immunity in
322 the population. Despite the neutralization resistance of VOC, vaccines remain highly effective in
323 preventing severe disease, suggesting the relevance of multiple potential mechanisms including antibody
324 Fc effector functions.

325 To this end, studying the antibody repertoire of neonates can mimic a passive transfer experiment
326 and has the potential to elucidate some of these mechanisms. Given the persistence and importance of
327 IgG in serum, the selective transfer of maternal IgG makes good biological sense, while the additional
328 passive transfer of maternal IgA present in breastmilk can provide added and more contemporaneous
329 protection at mucosal sites after birth. The evolutionary basis for the preferential transfer of IgGs with
330 certain phenotypes and activities is less clear. Whereas levels of the cytolytic IgG1 subclass in cord blood
331 typically exceed maternal blood, IgG3, arguably the most functionally active subclass, is less well
332 transferred. Transfer of IgG2, relatively inert in terms of effector function is typically also lower, while IgG4
333 levels appear to be either low enough or sufficiently variable in transfer efficiency that a global trend is
334 less clear⁶⁵. Additionally, while the importance of FcRn in transfer is clear, these patterns don't precisely
335 recapitulate the serum half-life or *in vitro* binding affinities of the IgG subclasses⁶⁶⁻⁶⁸. Further, differences
336 in the efficiency of transfer of antibodies with different pathogen- or antigen-specificities^{24,69}, as well as
337 with variable glycosylation⁷⁰⁻⁷², particularly in the variable region⁷⁰, are also associated with differences in
338 transfer efficiency. However, the means by which these attributes may contribute rather than simply
339 correlate with other, mechanistically relevant factors is unclear. The longitudinal profile of maternal

340 responses and total serum IgG levels clearly each play a role⁷³⁻⁷⁵, but samples are typically only tested at
341 a snapshot in time, often at delivery, as opposed to characterized with more continuous kinetic profiling.
342 Recent work has raised the possibility that additional processes or transporters, including FcγR, may play
343 a role^{44,46}.

344 Here, by comparing the SARS-CoV-2 spike-specific antibodies with those that recognize non-
345 sarbecovirus antigens, we assessed some of these factors. The generally poorer transfer of total and
346 each individual IgG subclass for SARS-reactive antibodies as compared to antigens that mothers were
347 presumed to be seropositive against before pregnancy suggests the importance of their more recent
348 induction and the contribution of the length of time over which maternal antibodies can be transferred in
349 the levels observed in neonates. In contrast, the general consistency between well and poorly transferred
350 subclasses, independent of specificity, points to this factor as generalizable. The relative efficiency of
351 SARS-CoV-2-specific antibody transfer between dyads with a history of vaccination as compared to
352 infection also differed somewhat, with generally improved transfer observed in vaccinated dyads,
353 consistent with a possible influence of inflammation associated with maternal infection.

354 Antibody functions were also variably well transferred between exposure history groups. ADCP,
355 ADCC, and ADCD activities against pertussis and tetanus antigens were generally elevated in cord blood,
356 while Wuhan SARS-CoV-2 spike-specific antibody effector functions were typically similar in vaccinated
357 and slightly reduced in convalescent cord as compared to maternal blood. For variants, however, this
358 decrease was dramatic in the context of natural infection, and some activities were essentially
359 undetectable in convalescent cord blood. The reduction in the breadth of antibody function paralleled the
360 reduced breadth of antibody binding and activity observed in natural infection overall, but the magnitude
361 of functional loss suggests that non-linearity, or threshold effects are at play in these activities. As has
362 been reported elsewhere, this pattern was also apparent in neutralization activity, which was greatly
363 reduced in cord blood. As compared to effector functions, broad neutralization activity was relatively
364 sparse, even in maternal blood. Among convalescent participants, even dyads with high Wuhan strain
365 neutralizing titers (>1:200) in maternal serum typically exhibited undetectable activity in cord blood. The
366 poorer neutralization activity of antibodies in cord blood than maternal serum is likely at least partly
367 attributable to the loss of contributions from IgM and IgA. Among other possible contributing factors, this
368 study identified differences in the affinity for antigen as potentially playing a role in defining breadth
369 across effector functions. Vaccination led to higher affinity antibodies against emergent coronaviruses
370 whereas natural infection induced higher affinity antibodies towards endemic coronaviruses. In turn, these
371 affinity profiles were consistent with antibody effector function breadth and potency profiles. Relative to
372 IgG1, the poorer transfer of IgG3, which can exhibit both greater effector function and greater apparent
373 affinity for antigen associated with its greater flexibility and hinge length, may also account for some of the
374 differences observed between maternal and cord blood and between vaccination and infection.

375 Consistent with prior reports⁷⁶, differences were observed in the relative levels of responses and
376 effector functions of SARS-CoV-2- and the endemic CoV OC43-specific antibodies that are associated

377 with spike stabilization and differences in cross-reactivity of antibodies directed to different sub-domains.
378 However, this study associates these functional distinctions with antibody affinity for antigen, finding that
379 polyclonal IgG pools with higher affinity antibodies exhibit greater effector function. While this study
380 cannot address the relative importance of one antibody function over another, neutralization activity was
381 considerably more limited than binding and effector functions, with less than one in ten dyads exhibiting
382 detectable neutralization of the Omicron strain. Low levels of binding antibodies to other emergent and
383 endemic CoV could be detected, and some were present at levels and with characteristics, such as high
384 affinity, sufficient to induce effector functions. Domain-level mapping of responses directed to endemic
385 CoV implicated the highly conserved S2 domain in these exceptionally broad responses, particularly in
386 association with natural infection, and prior work has suggested that they result from cross-reactive
387 clones^{76,77}. As VOC continue to emerge, and antigen-experienced populations benefit from mucosal
388 antibody and T cell responses, the relative importance of serum antibody neutralization titers, which have
389 served as a robust correlate of protection in early efficacy trials⁷⁸⁻⁸², may vary. Indeed, the mechanistic
390 relevance of neutralization, at least as typically tested *in vitro*, has been challenged by observations that
391 non-neutralizing and even antibodies that increase viral infectivity *in vitro* can provide protection *in vivo*
392 ^{83,84}. To this end, the broad recognition and function of antibodies raised by vaccination and natural
393 infection support the feasibility of “universal” COVID-19 vaccine development efforts.

394 Some limitations this study have already been alluded to. Maternal antibodies were sampled only
395 at the time of delivery, so their dynamic profile is not known. Further, the impact of timing of maternal
396 seropositivity could not be meaningfully evaluated given the relatively narrow window during gestational
397 ages at which exposure occurred. While study participants were enrolled at a similar timepoints in the
398 pandemic, they were drawn from geographically distinct populations. With the exception of neutralization,
399 antibody functions were evaluated in simplified rather than more ideally biologically authentic assays, and
400 cell lines rather than neonatal effector cells were employed to characterize activity in cord blood.
401 Sufficient sample volumes were not available to support evaluation of all specificities and activities in all
402 assays. The mechanisms whereby binding and functional assays show different transfer efficiencies are
403 likely to relate at least in part to differences in IgG subclass transfer, but further study would be needed to
404 more clearly resolve the roles of each antibody attribute to the efficiency of transfer and to each function.
405 Further, evidence of threshold effects was observed in several assays, but it remains unclear whether the
406 thresholds observed in the *in vitro* assays employed here are consistent those that might exist *in vivo*.
407 Lastly, while the relevance of antibody binding and effector functions tested in depth here to protection
408 from disease has been suggested in many prior studies⁸⁵, insights into the infection resilience of either
409 mothers or neonates in this study is lacking, and therefore relationships between these measures and
410 disease cannot be addressed here.

411 Overall, while numerous studies have shown the reduction in neutralization following viral
412 diversification over time, vaccines remain highly effective at preventing severe disease and death,
413 pointing to the contributions of other immune mechanisms. This study addresses the passive transfer and

414 inter-generational inheritance of functionally potent antibodies, and the relative ability of IgG antibodies to
415 drive broad recognition and effector activity that may contribute to protection from COVID-19. While
416 SARS-CoV-2-specific neutralizing activity was typically lost and antibody binding breadth and effector
417 function were typically reduced in cord as compared to maternal blood, effector functions were
418 substantially greater and broader following maternal vaccination than infection in both mothers and
419 infants. The biases in levels, isotypes, subclasses, affinity for antigen, neutralization and effector function
420 breadth and potency that associate with antigen exposure history have implications for protecting diverse
421 populations from ever-diversifying viral variants.

422

423 **Methods**

424 *Human Subjects*

425 Vaccinated participants (Israel), screened for lack of anti-N SARS-CoV-2 antibody responses, received
426 two doses of mRNA-encoded stabilized spike BNT162b2 (n=50) vaccine. Convalescent participants
427 (Belgium), had infection status defined by RT-PCR (n=38). While Wuhan was the dominant strain in
428 circulation at the time of sample collection, viruses were not typed. Naïve serum was obtained from a
429 commercial vendor (BioIVT) prior to approval of vaccines and was screened for anti-N SARS-CoV-2
430 antibody responses to exclude donors with previous infection. Characteristics for each study group are
431 described in **Supplemental Table 1**. While pregnant subjects completed their vaccination series in the
432 third trimester, and most convalescent subjects reported symptoms or tested positive in their third
433 trimester, elapsed time since most recent SARS-CoV-2 antigen exposure differed between cohorts, as
434 did time to delivery following diagnosis or receipt of the second vaccine dose. Study participants provided
435 informed written consent and studies were reviewed and approved by IRBs at individual collection sites
436 and Dartmouth.

437 *Fc Array*

438 Antigens were purchased from commercial sources or transiently expressed in Expi293 or HEK293 cells
439 and purified via affinity chromatography (**Supplemental Table 2**). Fc receptors were expressed and
440 purified as described previously⁸⁶. Antigen-specific antibodies were characterized using the Fc array
441 assay^{85,87}. Briefly, antigens were covalently coupled to MagPlex microspheres (Luminex Corporation).
442 Experimental controls included pooled human polyclonal serum IgG (IVIG), S309 an antibody from a
443 SARS-CoV patient that cross-reacts SARS-CoV and SARS-CoV-2, and VRC01, an HIV specific
444 antibody^{88,89}. Serum dilutions for profiling varied from 1:250 to 1:5000 depending on detection reagent.
445 Unless otherwise noted, concentrations tested were as listed in **Supplemental Table 2**. Antigen-specific
446 antibodies were detected by R-phycoerythrin-conjugated secondary reagents specific to human
447 immunoglobulin isotypes and subclasses and by Fc receptor tetramers^{90,91}. Median fluorescent intensity
448 data was acquired on a FlexMap 3D array reader (Luminex Corporation). Samples were run in technical
449 duplicate.

450 *Neutralization*

451 SARS-CoV-2 neutralizing antibodies (nAb) were quantified as previously reported^{85,92} for a subset of
452 maternal and matched cord blood serum samples (23 vaccinated, 26 convalescent, selected based on
453 having the highest binding antibody levels from among dyads with sufficient serum volumes available).
454 Briefly, serial dilutions of heat-inactivated serum (1/50 to 1/25,600 in EMEM supplemented with 2 mM L-
455 glutamine, 100 U/ml-100ug/mL of Pencillin-Streptomycin and 2% fetal bovine serum) were incubated for 1
456 hr at 37°C and 7% CO₂ with 3xTCID₁₀₀ of Wuhan strain (2019-nCoV-Italy-INMI1, 008 V-03893) and
457 Omicron strain BA.1 (B1.1.529, VLD20211207). A volume of 100 µL of sample-virus mixture was added
458 to 100 µL of Vero cells (18,000 cells/well) in a 96 well plate and cultured for five days at 37°C and 7%
459 CO₂. Cytopathic effects of viral growth were scored microscopically and the Reed-Muench method was

460 used to calculate the nAb titer that reduced the number of infected cells by 50% (NT₅₀), which was used
461 as a proxy for the nAb concentration in the sample. An internal reference standard composed of a pool of
462 serum from naturally infected and vaccinated adults was included in each nAb assay run, which was
463 calibrated against the International Standard 21/234 (NIBSC), in accordance with WHO guidance.

464 *Antibody-Dependent Cellular Phagocytosis (ADCP)*

465 Characterization of the phagocytic activity of serum antibodies was performed as described
466 previously^{85,93}. Briefly, 1 μM yellow-green fluorescent beads (Thermo Fisher, F8813) were covalently
467 conjugated to antigen. Beads were then incubated with serum samples for 4 hr with THP-1 cells (ATCC
468 TIB-202) at 37°C in 5% CO₂. Afterwards, cells were fixed and analyzed by flow cytometry using a
469 MACSQuant Analyzer (Miltenyi Biotec) to define the percentage of cells that phagocytosed one or more
470 fluorescent beads and the MFI of this population, the product of which was defined as the phagocytic
471 score (arbitrary units). Controls included wells with no added antibody were used to determine the level of
472 antibody-independent phagocytosis, S309 and VRC01 antibodies, and concentrated pooled polyclonal
473 serum IgG (Sigma Aldrich I4506); samples were tested in three biological replicates.

474 *Surrogate Reporter Cell Assay of Antibody-Dependent Cellular Cytotoxicity (ADCC)*

475 A CD16 activation reporter assay system was used as a surrogate for ADCC^{85,94}. First, high binding 96-
476 well plates were coated overnight at 4°C with 1 μg/mL of spike or RBD antigen. Following incubation,
477 plates were washed (PBS + 0.1% Tween20) and blocked (PBS + 2.5% BSA) at room temperature (RT)
478 for 1 hr. Following plate washing, 100,000 CD16- (FcγRIIIa) expressing Jurkat Lucia NFAT (Invivogen,
479 jktl-nfat-cd16) cells, cultured according to manufacturer's instructions, and dilute serum samples were
480 added to each well in cell culture media lacking antibiotics in a 200 μL volume. After 24 hrs of culture, 25
481 μL of supernatant from each well was transferred into a white 96 well plate to which 75 μL of quantiluc
482 substrate was added. After 10 min, luciferase signal was determined by reading plates on a SpectraMax
483 plate reader (Molecular Devices). Assay controls included cell stimulation cocktail (Thermo Fischer
484 Scientific, 00-4970-93) and ionomycin, buffers alone, spike-specific S309 and HIV-specific VRC01
485 monoclonal antibodies, and concentrated pooled polyclonal serum IgG (Sigma Aldrich I4506). Samples
486 were run in three biological replicates. In a prior study, this assay correlated well with killing activity
487 against a spike-expressing cell line⁸⁵.

488 *Antibody-Dependent Complement Deposition (ADCD)*

489 Antibody-dependent complement deposition (ADCD) experiments were performed essentially as
490 previously described^{85,95}. Serum samples were heat inactivated for 30 min at 56°C, prior to incubation for
491 2 hr at RT with assay microspheres. Human complement serum (Sigma, S1764) diluted 1:100 in gel
492 veronal buffer (Sigma-Aldrich, GVB++, G6514) was mixed with samples and microspheres at RT with
493 shaking for 1 hr. After washing, samples were incubated with murine anti-C3b (Cedarlane #CL7636AP) at
494 RT for 1 hr followed by staining with anti-mouse IgG1-PE secondary Ab (Southern Biotech #1070-09) at
495 RT for 30 min. A final wash was performed and samples were resuspended into Luminex sheath fluid and
496 MFI acquired on a FlexMap 3D reader. Assay controls included heat-inactivated complement, buffers
497 alone, spike-specific S309 and HIV-specific VRC01 monoclonal antibodies, and concentrated pooled
498 polyclonal serum IgG (Sigma Aldrich I4506). Samples were run in three biological replicates.

499 *Antibody depletion*

500 Antibody depletion experiments were performed on a subset of samples (n=15). Depletions were
501 performed using Ig capture select resins following manufacturer's instructions (Thermo Fisher) to deplete
502 IgM, IgA, or IgG. Depleted samples along with a mock control were tested in the multiplex assay to
503 measure depletion efficiency. Mock depletion samples followed the same protocol as the manufacturer's
504 instructions with the exception being that an irrelevant column matrix (Ni-NTA Thermo Fisher) was used.

505 *Octet Analysis*

506 Serum was purified for IgG using Melon Gel Purification kit (Thermo Fisher) following the manufacturer's
507 instructions. Binding affinities were determined using biolayer interferometry (BLI) on the Forte Bio Octet
508 system, essentially as previously described⁹⁶. Antigens were biotinylated with LC-LC no weigh biotin
509

510 (Thermo Fisher, A39257). After 30 min of reaction time, excess biotin was removed with Zeba desalting
511 columns (Thermo Fisher, 89882). To determine binding kinetics, biotinylated antigens were captured on
512 streptavidin Sax-2.0 tips (Forte Bio, 18-5136) and then incubated in dilute IgG. Briefly, biosensors were
513 first equilibrated in PBST (0.05% Tween-PBS) for 180s and activated by dipping into 10 mM glycine (pH
514 1.7) for 20s and PBST 20s for three cycles. Biosensors were then loaded with biotinylated antigen at
515 1mg/ml in PBST for 300s, and dipped into PBST for 300s to reach baseline, prior to a 300s association
516 phase in which they were dipped into IgG, and a 300s dissociation phase in which they were dipped into
517 PBST. Assessments were performed across 3-fold serial dilutions of IgG ranging from 10 mM to 0.013
518 mM. Sample traces of a single concentration (10mM) were plotted for representative results. Tips were
519 regenerated for 20s for each condition in 10mM glycine pH 1.7. Data was aligned and corrected between
520 steps as needed, and signal observed in reference sample wells, comprised of tips loaded with antigen
521 but not dipped into IgG, was subtracted. For kinetic analysis, a 1:1 association and dissociation model
522 was selected in Forte Bio data analysis 7.0 software in order to determine K_D .

523

524 *Data Analysis and Statistical Quantification*

525 UMAP plots were generated in Python (version 3.11) using the umap-learn package (version0.4).
526 Volcano plots were generated in R (version 4.3) using ggplot2. Statistical analysis was performed in
527 GraphPad Prism (version 9.7). Statistical test are described in the respective figure legends. Breadth-
528 potency curves were defined as the proportion of antigen-specificities exhibiting a signal above a given
529 intensity. Curves were generated using the LOWESS curve fit method in Prism for each respective
530 subject group. Breadth scores were calculated by taking the geometric mean across antigen specificities
531 for each subject. The sample size for each figure includes all subjects from their respective groups unless
532 otherwise noted.

533

534

535 **Acknowledgements**

536 We would like to thank all participants who enrolled in this study and the study and laboratory staff who
537 helped collect and process the samples. A number of antigen expression constructs were provided by
538 Dr. Jason McLellan (UT Austin) and the positive control mAb S309 was provided by Dr. Jiwon Lee
539 (Dartmouth). The following reagent was produced under HHSN272201400008C and obtained through
540 BEI Resources, NIAID, NIH: Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related
541 Coronavirus 2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from Baculovirus, NR-52307.
542 The following reagent was deposited by the Centers for Disease Control and Prevention and obtained
543 through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-52281.

544

545 **Conflict of Interest**

546 M.E.A. reports grant support from Be Bio and Moderna unrelated to COVID-19 vaccines.

547

548 **Funding**

549 This work was supported in part by the National Institute of Allergy and Infectious Diseases
550 1U19AI145825, National Cancer Institute P30 CA 023108-41, National Institute of General Medical
551 Sciences P20-GM113132. A.M. is Research Director at the F.R.S., FNRS, Belgium.

552 **References:**

- 553 1 Ahmad, F. B., Cisewski, J. A., Xu, J. & Anderson, R. N. COVID-19 Mortality Update - United States,
554 2022. *MMWR Morb Mortal Wkly Rep* **72**, 493-496 (2023).
555 <https://doi.org/10.15585/mmwr.mm7218a4>
- 556 2 Zohar, T. *et al.* Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality.
557 *Cell* **183**, 1508-1519.e1512 (2020). <https://doi.org/10.1016/j.cell.2020.10.052>
- 558 3 Feng, S. *et al.* Correlates of protection against symptomatic and asymptomatic SARS-CoV-2
559 infection. *Nat Med* **27**, 2032-2040 (2021). <https://doi.org/10.1038/s41591-021-01540-1>
- 560 4 Pegu, A. *et al.* Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.
561 *Science* **373**, 1372-1377 (2021). <https://doi.org/10.1126/science.abj4176>
- 562 5 Rees-Spear, C. *et al.* The effect of spike mutations on SARS-CoV-2 neutralization. *Cell Rep* **34**,
563 108890 (2021). <https://doi.org/10.1016/j.celrep.2021.108890>
- 564 6 Schmidt, F. *et al.* Plasma Neutralization of the SARS-CoV-2 Omicron Variant. *N Engl J Med* **386**,
565 599-601 (2022). <https://doi.org/10.1056/NEJMc2119641>
- 566 7 Sievers, B. L. *et al.* Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced
567 neutralizing activity against Beta and Omicron pseudoviruses. *Sci Transl Med* **14**, eabn7842
568 (2022). <https://doi.org/10.1126/scitranslmed.abn7842>
- 569 8 Wang, L. *et al.* Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies
570 elicited by COVID-19 mRNA vaccines. *Nat Commun* **13**, 4350 (2022).
571 <https://doi.org/10.1038/s41467-022-31929-6>
- 572 9 Wang, P. *et al.* Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature* **593**, 130-
573 135 (2021). <https://doi.org/10.1038/s41586-021-03398-2>
- 574 10 Wang, Z. *et al.* mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. *Nature*
575 **592**, 616-622 (2021). <https://doi.org/10.1038/s41586-021-03324-6>
- 576 11 Zhou, D. *et al.* Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-
577 induced sera. *Cell* **184**, 2348-2361.e2346 (2021). <https://doi.org/10.1016/j.cell.2021.02.037>
- 578 12 Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* **384**,
579 403-416 (2021). <https://doi.org/10.1056/NEJMoa2035389>
- 580 13 Jackson, L. A. *et al.* An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *N Engl J Med*
581 **383**, 1920-1931 (2020). <https://doi.org/10.1056/NEJMoa2022483>
- 582 14 Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*
583 **383**, 2603-2615 (2020). <https://doi.org/10.1056/NEJMoa2034577>
- 584 15 Yang, Y. J. *et al.* Association of Gestational Age at Coronavirus Disease 2019 (COVID-19)
585 Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
586 Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at
587 Delivery. *Obstetrics & Gynecology* **139**, 373-380 (2022).
588 <https://doi.org/10.1097/aog.0000000000004693>
- 589 16 Fleming-Dutra, K. E. *et al.* Safety and Effectiveness of Maternal COVID-19 Vaccines Among
590 Pregnant People and Infants. *Obstetrics and Gynecology Clinics of North America* **50**, 279-297
591 (2023). <https://doi.org/https://doi.org/10.1016/j.ogc.2023.02.003>
- 592 17 Prasad, S. *et al.* Systematic review and meta-analysis of the effectiveness and perinatal
593 outcomes of COVID-19 vaccination in pregnancy. *Nature Communications* **13**, 2414 (2022).
594 <https://doi.org/10.1038/s41467-022-30052-w>
- 595 18 Schrag, S. J. *et al.* Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically
596 Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in
597 the United States. *JAMA Netw Open* **5**, e2233273 (2022).
598 <https://doi.org/10.1001/jamanetworkopen.2022.33273>

- 599 19 Piekos, S. N., Price, N. D., Hood, L. & Hadlock, J. J. The impact of maternal SARS-CoV-2 infection
600 and COVID-19 vaccination on maternal-fetal outcomes. *Reprod Toxicol* **114**, 33-43 (2022).
601 <https://doi.org/10.1016/j.reprotox.2022.10.003>
- 602 20 Halasa, N. B. *et al.* Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants.
603 *N Engl J Med* **387**, 109-119 (2022). <https://doi.org/10.1056/NEJMoa2204399>
- 604 21 Shimabukuro, T. T. *et al.* Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant
605 Persons. *N Engl J Med* **384**, 2273-2282 (2021). <https://doi.org/10.1056/NEJMoa2104983>
- 606 22 Zauche, L. H. *et al.* Receipt of mRNA Covid-19 Vaccines and Risk of Spontaneous Abortion. *N Engl*
607 *J Med* **385**, 1533-1535 (2021). <https://doi.org/10.1056/NEJMc2113891>
- 608 23 Etti, M. *et al.* Maternal vaccination: a review of current evidence and recommendations. *Am J*
609 *Obstet Gynecol* **226**, 459-474 (2022). <https://doi.org/10.1016/j.ajog.2021.10.041>
- 610 24 Palmeira, P., Quinello, C., Silveira-Lessa, A. L., Zago, C. A. & Carneiro-Sampaio, M. IgG placental
611 transfer in healthy and pathological pregnancies. *Clin Dev Immunol* **2012**, 985646 (2012).
612 <https://doi.org/10.1155/2012/985646>
- 613 25 Fouda, G. G., Martinez, D. R., Swamy, G. K. & Permar, S. R. The Impact of IgG Transplacental
614 Transfer on Early Life Immunity. *ImmunoHorizons* **2**, 14-25 (2018).
615 <https://doi.org/10.4049/immunohorizons.1700057>
- 616 26 Rao, S. *et al.* Postacute Sequelae of SARS-CoV-2 in Children. *Pediatrics* **153** (2024).
617 <https://doi.org/10.1542/peds.2023-062570>
- 618 27 Feldstein, L. R. *et al.* Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. *New*
619 *England Journal of Medicine* **383**, 334-346 (2020). <https://doi.org/doi:10.1056/NEJMoa2021680>
- 620 28 Stock, S. J. *et al.* SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in
621 Scotland. *Nat Med* **28**, 504-512 (2022). <https://doi.org/10.1038/s41591-021-01666-2>
- 622 29 Stock, S. J. *et al.* Pregnancy outcomes after SARS-CoV-2 infection in periods dominated by delta
623 and omicron variants in Scotland: a population-based cohort study. *Lancet Respir Med* **10**, 1129-
624 1136 (2022). [https://doi.org/10.1016/s2213-2600\(22\)00360-5](https://doi.org/10.1016/s2213-2600(22)00360-5)
- 625 30 Rahmati, M. *et al.* Effects of COVID-19 vaccination during pregnancy on SARS-CoV-2 infection
626 and maternal and neonatal outcomes: A systematic review and meta-analysis. *Rev Med Virol* **33**,
627 e2434 (2023). <https://doi.org/10.1002/rmv.2434>
- 628 31 Borghi, S. *et al.* FcRn, but not FcγRs, drives maternal-fetal transplacental transport of human IgG
629 antibodies. *Proceedings of the National Academy of Sciences* **117**, 12943-12951 (2020).
630 <https://doi.org/doi:10.1073/pnas.2004325117>
- 631 32 Vaccaro, C., Bawdon, R., Wanjie, S., Ober, R. J. & Ward, E. S. Divergent activities of an
632 engineered antibody in murine and human systems have implications for therapeutic
633 antibodies. *Proc Natl Acad Sci U S A* **103**, 18709-18714 (2006).
634 <https://doi.org/10.1073/pnas.0606304103>
- 635 33 Firan, M. *et al.* The MHC class I-related receptor, FcRn, plays an essential role in the
636 maternofetal transfer of gamma-globulin in humans. *Int Immunol* **13**, 993-1002 (2001).
637 <https://doi.org/10.1093/intimm/13.8.993>
- 638 34 Ghetie, V. & Ward, E. S. FcRn: the MHC class I-related receptor that is more than an IgG
639 transporter. *Immunol Today* **18**, 592-598 (1997). [https://doi.org/10.1016/s0167-5699\(97\)01172-](https://doi.org/10.1016/s0167-5699(97)01172-9)
640 [9](https://doi.org/10.1016/s0167-5699(97)01172-9)
- 641 35 Burmeister, W. P., Huber, A. H. & Bjorkman, P. J. Crystal structure of the complex of rat neonatal
642 Fc receptor with Fc. *Nature* **372**, 379-383 (1994). <https://doi.org/10.1038/372379a0>
- 643 36 Wang, X. *et al.* Dynamic changes of acquired maternal SARS-CoV-2 IgG in infants. *Sci Rep* **11**,
644 8021 (2021). <https://doi.org/10.1038/s41598-021-87535-x>

- 645 37 Joseph, N. T. *et al.* Maternal Antibody Response, Neutralizing Potency, and Placental Antibody
646 Transfer After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. *Obstet*
647 *Gynecol* **138**, 189-197 (2021). <https://doi.org/10.1097/aog.0000000000004440>
- 648 38 Atyeo, C. *et al.* Compromised SARS-CoV-2-specific placental antibody transfer. *Cell* **184**, 628-
649 642.e610 (2021). <https://doi.org/10.1016/j.cell.2020.12.027>
- 650 39 Flannery, D. D. *et al.* Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies
651 and Placental Transfer Ratios. *JAMA Pediatr* **175**, 594-600 (2021).
652 <https://doi.org/10.1001/jamapediatrics.2021.0038>
- 653 40 Kugelman, N. *et al.* Maternal and Neonatal SARS-CoV-2 Immunoglobulin G Antibody Levels at
654 Delivery After Receipt of the BNT162b2 Messenger RNA COVID-19 Vaccine During the Second
655 Trimester of Pregnancy. *JAMA Pediatr* **176**, 290-295 (2022).
656 <https://doi.org/10.1001/jamapediatrics.2021.5683>
- 657 41 Mithal, L. B., Otero, S., Shanes, E. D., Goldstein, J. A. & Miller, E. S. Cord blood antibodies
658 following maternal coronavirus disease 2019 vaccination during pregnancy. *Am J Obstet Gynecol*
659 **225**, 192-194 (2021). <https://doi.org/10.1016/j.ajog.2021.03.035>
- 660 42 Zdanowski, W. & Waśniewski, T. Evaluation of SARS-CoV-2 Spike Protein Antibody Titers in Cord
661 Blood after COVID-19 Vaccination during Pregnancy in Polish Healthcare Workers: Preliminary
662 Results. *Vaccines (Basel)* **9** (2021). <https://doi.org/10.3390/vaccines9060675>
- 663 43 Soysal, A., Bilazer, C., Gönüllü, E., Barın, E. & Çivilibal, M. Cord blood antibody following
664 maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy. *Hum*
665 *Vaccin Immunother* **17**, 3484-3486 (2021). <https://doi.org/10.1080/21645515.2021.1947099>
- 666 44 Rosenberg, Y. J. *et al.* Evidence for the Role of a Second Fc-Binding Receptor in Placental IgG
667 Transfer in Nonhuman Primates. *mBio* **14**, e00341-00323 (2023).
668 <https://doi.org/doi:10.1128/mbio.00341-23>
- 669 45 Martinez, D. R., Fouda, G. G., Peng, X., Ackerman, M. E. & Permar, S. R. Noncanonical placental
670 Fc receptors: What is their role in modulating transplacental transfer of maternal IgG? *PLoS*
671 *Pathog* **14**, e1007161 (2018). <https://doi.org/10.1371/journal.ppat.1007161>
- 672 46 Langel, S. N., Otero, C. E., Martinez, D. R. & Permar, S. R. Maternal gatekeepers: How maternal
673 antibody Fc characteristics influence passive transfer and infant protection. *PLoS Pathog* **16**,
674 e1008303 (2020). <https://doi.org/10.1371/journal.ppat.1008303>
- 675 47 Flannery, D. D. *et al.* Comparison of Maternal and Neonatal Antibody Levels After COVID-19
676 Vaccination vs SARS-CoV-2 Infection. *JAMA Network Open* **5**, e2240993-e2240993 (2022).
677 <https://doi.org/10.1001/jamanetworkopen.2022.40993>
- 678 48 Rottenstreich, A. *et al.* Timing of SARS-CoV-2 vaccination during the third trimester of pregnancy
679 and transplacental antibody transfer: a prospective cohort study. *Clinical Microbiology and*
680 *Infection* **28**, 419-425 (2022). <https://doi.org/https://doi.org/10.1016/j.cmi.2021.10.003>
- 681 49 Beharier, O. *et al.* Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and
682 BNT162b2 mRNA COVID-19 vaccine. *The Journal of Clinical Investigation* **131** (2021).
683 <https://doi.org/10.1172/JCI150319>
- 684 50 Atyeo, C. *et al.* COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in
685 pregnant, lactating, and nonpregnant women. *Sci Transl Med* **13**, eabi8631 (2021).
686 <https://doi.org/10.1126/scitranslmed.abi8631>
- 687 51 Adhikari, E. H. *et al.* Diverging Maternal and Cord Antibody Functions From SARS-CoV-2 Infection
688 and Vaccination in Pregnancy. *The Journal of Infectious Diseases* (2023).
689 <https://doi.org/10.1093/infdis/jiad421>
- 690 52 Atyeo, C. G. *et al.* Maternal immune response and placental antibody transfer after COVID-19
691 vaccination across trimester and platforms. *Nature Communications* **13**, 3571 (2022).
692 <https://doi.org/10.1038/s41467-022-31169-8>

- 693 53 Garrett, M. E. *et al.* Comprehensive characterization of the antibody responses to SARS-CoV-2
694 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection. *eLife*
695 **11**, e73490 (2022). <https://doi.org/10.7554/eLife.73490>
- 696 54 Puhach, O. *et al.* SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune
697 responses. *eBioMedicine* **98** (2023). <https://doi.org/10.1016/j.ebiom.2023.104893>
- 698 55 Sano, K. *et al.* SARS-CoV-2 vaccination induces mucosal antibody responses in previously
699 infected individuals. *Nat Commun* **13**, 5135 (2022). [https://doi.org/10.1038/s41467-022-32389-](https://doi.org/10.1038/s41467-022-32389-8)
700 [8](https://doi.org/10.1038/s41467-022-32389-8)
- 701 56 Espino, A. M. *et al.* The Anti-SARS-CoV-2 IgG1 and IgG3 Antibody Isotypes with Limited
702 Neutralizing Capacity against Omicron Elicited in a Latin Population a Switch toward IgG4 after
703 Multiple Doses with the mRNA Pfizer-BioNTech Vaccine. *Viruses* **16** (2024).
704 <https://doi.org/10.3390/v16020187>
- 705 57 Kizsel, P. *et al.* Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2
706 mRNA vaccination depends on prior infection history. *Sci Rep* **13**, 13166 (2023).
707 <https://doi.org/10.1038/s41598-023-40103-x>
- 708 58 Poolchanuan, P. *et al.* Dynamics of Different Classes and Subclasses of Antibody Responses to
709 Severe Acute Respiratory Syndrome Coronavirus 2 Variants after Coronavirus Disease 2019 and
710 CoronaVac Vaccination in Thailand. *mSphere* **8**, e00465-00422 (2023).
711 <https://doi.org/doi:10.1128/msphere.00465-22>
- 712 59 Jacobs, E. T. *et al.* Understanding low COVID-19 booster uptake among US adults. *Vaccine* **41**,
713 6221-6226 (2023). <https://doi.org/10.1016/j.vaccine.2023.08.080>
- 714 60 Zhao, F., Zai, X., Zhang, Z., Xu, J. & Chen, W. Challenges and developments in universal vaccine
715 design against SARS-CoV-2 variants. *npj Vaccines* **7**, 167 (2022). [https://doi.org/10.1038/s41541-](https://doi.org/10.1038/s41541-022-00597-4)
716 [022-00597-4](https://doi.org/10.1038/s41541-022-00597-4)
- 717 61 Rössler, A., Riepler, L., Bante, D., Laer, D. v. & Kimpel, J. SARS-CoV-2 Omicron Variant
718 Neutralization in Serum from Vaccinated and Convalescent Persons. *New England Journal of*
719 *Medicine* **386**, 698-700 (2022). <https://doi.org/doi:10.1056/NEJMc2119236>
- 720 62 Govindaraj, S. *et al.* COVID-19 vaccine induced poor neutralization titers for SARS-CoV-2 omicron
721 variants in maternal and cord blood. *Front Immunol* **14**, 1211558 (2023).
722 <https://doi.org/10.3389/fimmu.2023.1211558>
- 723 63 Lv, H. *et al.* Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.
724 *Cell Reports* **31** (2020). <https://doi.org/10.1016/j.celrep.2020.107725>
- 725 64 Murray, S. M. *et al.* The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection
726 and vaccine responses. *Nature Reviews Immunology* **23**, 304-316 (2023).
727 <https://doi.org/10.1038/s41577-022-00809-x>
- 728 65 Clements, T. *et al.* Update on Transplacental Transfer of IgG Subclasses: Impact of Maternal and
729 Fetal Factors. *Front Immunol* **11**, 1920 (2020). <https://doi.org/10.3389/fimmu.2020.01920>
- 730 66 Mankarious, S. *et al.* The half-lives of IgG subclasses and specific antibodies in patients with
731 primary immunodeficiency who are receiving intravenously administered immunoglobulin. *J Lab*
732 *Clin Med* **112**, 634-640 (1988).
- 733 67 Irani, V. *et al.* Molecular properties of human IgG subclasses and their implications for designing
734 therapeutic monoclonal antibodies against infectious diseases. *Molecular Immunology* **67**, 171-
735 182 (2015). <https://doi.org/https://doi.org/10.1016/j.molimm.2015.03.255>
- 736 68 Stapleton, N. M. *et al.* Reduced FcRn-mediated transcytosis of IgG2 due to a missing Glycine in
737 its lower hinge. *Sci Rep* **9**, 7363 (2019). <https://doi.org/10.1038/s41598-019-40731-2>
- 738 69 Dolatshahi, S. *et al.* Selective transfer of maternal antibodies in preterm and fullterm children.
739 *Sci Rep* **12**, 14937 (2022). <https://doi.org/10.1038/s41598-022-18973-4>

- 740 70 Gao, C., Chen, Q., Hao, X. & Wang, Q. Immunomodulation of Antibody Glycosylation through the
741 Placental Transfer. *Int J Mol Sci* **24** (2023). <https://doi.org/10.3390/ijms242316772>
- 742 71 Jennewein, M. F. *et al.* Fc Glycan-Mediated Regulation of Placental Antibody Transfer. *Cell* **178**,
743 202-215.e214 (2019). <https://doi.org/https://doi.org/10.1016/j.cell.2019.05.044>
- 744 72 Adhikari, E. H. *et al.* Diverging Maternal and Cord Antibody Functions From SARS-CoV-2 Infection
745 and Vaccination in Pregnancy. *The Journal of Infectious Diseases* **229**, 462-472 (2023).
746 <https://doi.org/10.1093/infdis/jiad421>
- 747 73 Malek, A., Sager, R. & Schneider, H. Maternal-fetal transport of immunoglobulin G and its
748 subclasses during the third trimester of human pregnancy. *Am J Reprod Immunol* **32**, 8-14
749 (1994). <https://doi.org/10.1111/j.1600-0897.1994.tb00873.x>
- 750 74 Simister, N. E. Placental transport of immunoglobulin G. *Vaccine* **21**, 3365-3369 (2003).
751 [https://doi.org/10.1016/s0264-410x\(03\)00334-7](https://doi.org/10.1016/s0264-410x(03)00334-7)
- 752 75 Wilcox, C. R., Holder, B. & Jones, C. E. Factors Affecting the FcRn-Mediated Transplacental
753 Transfer of Antibodies and Implications for Vaccination in Pregnancy. *Front Immunol* **8**, 1294
754 (2017). <https://doi.org/10.3389/fimmu.2017.01294>
- 755 76 Crowley, A. R. *et al.* Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-
756 CoV-2 infection but not vaccination with stabilized spike. *eLife* **11**, e75228 (2022).
757 <https://doi.org/10.7554/eLife.75228>
- 758 77 Wang, C. *et al.* Antigenic structure of the human coronavirus OC43 spike reveals exposed and
759 occluded neutralizing epitopes. *Nature Communications* **13**, 2921 (2022).
760 <https://doi.org/10.1038/s41467-022-30658-0>
- 761 78 Goldblatt, D., Alter, G., Crotty, S. & Plotkin, S. A. Correlates of protection against SARS-CoV-2
762 infection and COVID-19 disease. *Immunol Rev* **310**, 6-26 (2022).
763 <https://doi.org/10.1111/imr.13091>
- 764 79 Khoury, D. S. *et al.* Correlates of Protection, Thresholds of Protection, and Immunobridging
765 among Persons with SARS-CoV-2 Infection. *Emerg Infect Dis* **29**, 381-388 (2023).
766 <https://doi.org/10.3201/eid2902.221422>
- 767 80 Gilbert, P. B. *et al.* A Covid-19 Milestone Attained — A Correlate of Protection for Vaccines. *New*
768 *England Journal of Medicine* **387**, 2203-2206 (2022).
769 <https://doi.org/doi:10.1056/NEJMp2211314>
- 770 81 Garcia-Beltran, W. F. *et al.* COVID-19-neutralizing antibodies predict disease severity and
771 survival. *Cell* **184**, 476-488.e411 (2021). <https://doi.org/10.1016/j.cell.2020.12.015>
- 772 82 Salazar, E. *et al.* Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-
773 binding domain IgG correlate with virus neutralization. *The Journal of Clinical Investigation* **130**,
774 6728-6738 (2020). <https://doi.org/10.1172/JCI141206>
- 775 83 Pierre, C. N. *et al.* Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice
776 against severe disease using Fc-mediated effector functions. *PLoS Pathog* **20**, e1011569 (2024).
777 <https://doi.org/10.1371/journal.ppat.1011569>
- 778 84 Li, D. *et al.* In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing
779 antibodies. *Cell* **184**, 4203-4219.e4232 (2021). <https://doi.org/10.1016/j.cell.2021.06.021>
- 780 85 Hederman, A. P. *et al.* SARS-CoV-2 vaccination elicits broad and potent antibody effector
781 functions to variants of concern in vulnerable populations. *Nature Communications* **14**, 5171
782 (2023). <https://doi.org/10.1038/s41467-023-40960-0>
- 783 86 Boesch, A. W. *et al.* Highly parallel characterization of IgG Fc binding interactions. *MAbs* **6**, 915-
784 927 (2014). <https://doi.org/10.4161/mabs.28808>
- 785 87 Brown, E. P. *et al.* High-throughput, multiplexed IgG subclassing of antigen-specific antibodies
786 from clinical samples. *J Immunol Methods* **386**, 117-123 (2012).
787 <https://doi.org/10.1016/j.jim.2012.09.007>

- 788 88 Pinto, D. *et al.* Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
789 *Nature* **583**, 290-295 (2020). <https://doi.org/10.1038/s41586-020-2349-y>
- 790 89 Wu, X. *et al.* Rational design of envelope identifies broadly neutralizing human monoclonal
791 antibodies to HIV-1. *Science* **329**, 856-861 (2010). <https://doi.org/10.1126/science.1187659>
- 792 90 Brown, E. P. *et al.* Multiplexed Fc array for evaluation of antigen-specific antibody effector
793 profiles. *J Immunol Methods* **443**, 33-44 (2017). <https://doi.org/10.1016/j.jim.2017.01.010>
- 794 91 Brown, E. P. *et al.* Optimization and qualification of an Fc Array assay for assessments of
795 antibodies against HIV-1/SIV. *J Immunol Methods* **455**, 24-33 (2018).
796 <https://doi.org/10.1016/j.jim.2018.01.013>
- 797 92 Arien, K. K. *et al.* Three doses of BNT162b2 vaccine confer neutralising antibody capacity against
798 the SARS-CoV-2 Omicron variant. *NPJ Vaccines* **7**, 35 (2022). [https://doi.org/10.1038/s41541-](https://doi.org/10.1038/s41541-022-00459-z)
799 [022-00459-z](https://doi.org/10.1038/s41541-022-00459-z)
- 800 93 Ackerman, M. E. *et al.* A robust, high-throughput assay to determine the phagocytic activity of
801 clinical antibody samples. *J Immunol Methods* **366**, 8-19 (2011).
802 <https://doi.org/10.1016/j.jim.2010.12.016>
- 803 94 Butler, S. E. *et al.* Distinct Features and Functions of Systemic and Mucosal Humoral Immunity
804 Among SARS-CoV-2 Convalescent Individuals. *Frontiers in Immunology* **11** (2021).
805 <https://doi.org/10.3389/fimmu.2020.618685>
- 806 95 Fischinger, S. *et al.* A high-throughput, bead-based, antigen-specific assay to assess the ability of
807 antibodies to induce complement activation. *J Immunol Methods* **473**, 112630 (2019).
808 <https://doi.org/10.1016/j.jim.2019.07.002>
- 809 96 Tolbert, W. D. *et al.* Decoding human-macaque interspecies differences in Fc-effector functions:
810 The structural basis for CD16-dependent effector function in Rhesus macaques. *Front Immunol*
811 **13**, 960411 (2022). <https://doi.org/10.3389/fimmu.2022.960411>
- 812




Figure 1: Antibody isotype, magnitude, and breadth across SARS-CoV-2 VOC in maternal and cord blood samples following vaccination or natural infection. A. Coronavirus-specific antibody response features after dimensional reduction in maternal (filled) and cord (open) samples among convalescent (n = 38) (blue) or vaccinated (n = 50) (green) individuals. **B.** Volcano plot presenting the fold-change (x-axis) and statistical significance (Mann Whitney test, y-axis) of differences between convalescent and vaccinated participants. Antibody isotype is indicated by shape, with RBD and whole spike indicated in hollow and filled symbols, respectively. SARS-CoV-2 variant is indicated by color. **C.** Median Fluorescent Intensity (MFI) of IgG responses to spike of SARS CoV-2 VOCs as defined by multiplex assay for IgM (top), IgA (middle), and IgG (bottom). Responses among SARS-CoV-2 naïve subjects (n = 38) are shown in black. Bar indicates the median response. **D.** Breadth-potency curves represent the fraction of subjects with a response exceeding a given level for IgG antibody responses across the panel of VOC. Population means are shown with a thick line, and individual subjects illustrated in thin lines. **E.** IgG breadth scores for each subject. Bar indicates the median. Statistical significance was defined by ANOVA Kruskal–Wallis test with Dunn’s correction and $\alpha=0.05$ (* $p<0.05$, ** $p<0.01$, *** $p<0.001$, **** $p<0.0001$).




Figure 2: Vaccination and infection elicit distinct IgG subclass and Fc receptor breadth in cord blood.

A. Breadth–potency curves representing the fraction of subjects with a response exceeding a given level for each IgG subclass (left) and for binding to FcR (right) across the panel of VOC in cord blood samples following maternal vaccination or infection. Population mean is shown with a thick line, and individual subjects are illustrated in thin lines. **B.** IgG subclass (top) and FcR binding (bottom) breadth scores for each cord blood samples following maternal vaccination (filled) or infection (hollow). Statistical significance was defined by ANOVA Kruskal–Wallis test with Dunn’s correction and $\alpha=0.05$ (** $p<0.01$, *** $p<0.001$, **** $p<0.0001$). **C.** Transfer ratio (cord/maternal levels) of antigen-specific (SARS: Wuhan and Omicron Spike; Control: Pertussis and Tetanus) IgG subclasses in vaccinated (green) and convalescent (blue) dyads. **D.** Median transfer ratios of each SARS-CoV-2 spike VOC as compared to control antigens by subclass. Bars indicate median.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




Figure 3: mRNA vaccination results in superior breadth of SARS-CoV-2-specific Ab effector

function and neutralization in cord blood. **A.** Ab effector functions in cord blood from vaccinated (top, green shading) and convalescent (bottom, blue shading) cord blood for SARS spike variants or pertussis and tetanus control (red box) antigens. Phagocytosis, ADCC, and Complement deposition activities were assessed at each of three serum dilutions (1:50, 1:100, 1:250). Functional activity is reported in arbitrary units (AU), relative light units (RLU), and median fluorescent intensity (MFI). **Inset.** Functional breadth scores across variants in maternal, cord, and naïve subject samples. Statistical significance was defined by ANOVA Kruskal–Wallis test with Dunn’s correction and $\alpha = 0.05$. **B–C.** Transfer ratios (cord/maternal) of Fc effector functions to indicated antigens in vaccinated (green) or convalescent (blue) dyads at the 1:50 dilution for individual antigens (**B**) and for the set of SARS and control antigens (**C**). **D.** Neutralization titers (NT_{50}) observed for a subset of vaccinated ($n=23$) (green) and convalescent ($n=26$) (blue) maternal and cord samples against Wuhan (black) and Omicron (orange) strains. The limit of detection (LOD) is indicated by the horizontal dotted line. **E.** Transfer ratios of neutralization activity. Bars indicates median. Unless otherwise noted, data presented includes samples from 37 naïve subjects, and 50 vaccinated and 38 convalescent dyads.




Figure 4: Contributions of each isotype to antibody effector functions in cord and maternal blood.

Maternal (M) and cord (C) blood samples from vaccinated (green, n=15) and convalescent (n=15) dyads depleted of IgM (top), IgA (center), and IgG (bottom) antibodies. **A-D.** Binding levels (**A**, left) and effector functions (**B-D**) (right) to Wuhan spike protein were measured on mock and depleted (+) samples for each isotype to measure efficiency of each depletion and the impact on antibody activity against Wuhan spike antigen. Mock and depleted (+) samples were compared using a paired mixed effect model corrected for multiple hypothesis testing using the Benjamini, Krieger, and Yekutieli to control the false discovery rate ($*q < Q$, where $Q=0.05$). Functional activity is reported in arbitrary units (AU), relative light units (RLU), and median fluorescent intensity (MFI).




Figure 5. Cross reactivity to emergent and endemic coronavirus. **A.** Coronavirus-specific antibody response features after dimensional reduction in maternal (filled) and cord (open) samples among convalescent ($n = 38$) (blue) or vaccinated ($n = 50$) (green) individuals. Naive subjects ($n=37$) are shown in black. IgG binding experiments were performed at 1:2500 and 1:5000 dilutions. IgM, IgA, and IgG binding responses to SARS-CoV-1 S and MERS S. **B.** IgM, IgA, and IgG binding responses to endemic coronaviruses HKU1, OC43, NL63, and 229E. All antigens are full length spike. **C.** ADCP, ADCC, and ADCD functional responses to SARS-CoV-1 spike. **D.** ADCP, ADCC, and ADCD responses against OC43 S. **E.** IgM, IgA, and IgG antibody binding profiles to endemic coronavirus antigens in other conformations (HKU1 S1, OC43S2, OC43S2P, NL62 S1, 229E S1). **F.** ADCP, ADCC, and ADCD responses against OC43 S2 antigen. Functional activity is reported in arbitrary units (AU), relative light units (RLU), and median fluorescent intensity (MFI). **G.** Antibody association and dissociation traces for affinity analysis of binding to OC43 S2 for a subset of samples from each group ($n=5$) at 10 mM. **H.** Binding of each subject to the panel of antigens measured. **I.** Heatmap antibody affinities (K_D M) to each antigen tested. Darker red denotes higher affinity binding interaction.